Biotechnology valuation and governance: Drug development and board of directors composition
Requires Subscription or Fee PDF


board composition
drug development


This paper examines the valuation of biotechnology firms and measure firm value relative to the firms’ drug development pipelines, alliances with other firms, and the varied composition of those firms’ boards of directors.  Unsurprisingly, the advancement of drugs in the pipeline is associated with increased valuation, and the failure of drugs in testing is found to have negative impacts.  Findings do not support the notion that companies engaged in partnerships or alliances have better performance. Extending prior research, the study finds that the presence of medical doctors on the boards of directors is significantly positively associated with the price-to-book ratio and firm value. Drug approvals seemed less likely for small cap firms; this outcome is likely the result of small cap firms with more promising prospects being acquired, and exiting “small cap†status. Among other findings, a higher number of drug approvals among such targeted diseases as AIDS and cancer are observed; modestly higher approval rates are observed in concert with a relatively higher proportion of financiers – such as hedge fund managers and investment bankers – on biotechnology boards.  Findings are important to the investor, the biotechnology manager and the regulator.
Requires Subscription or Fee PDF


Agnew, B. "When Pharma merges, R&D is the Dowry." Science 287 (2000): 1952-953.

Barnhart, Scott W., and Stuart Rosenstein. "Board Composition, Managerial Ownership, and Firm Performance: An Empirical Analysis." The Financial Review 33.4 (1998): 1-16.

Baum, J. A., T. Calabrese, and B. S. Silverman. "Don't go it alone: Alliance network composition and startups' performance in Canadian biotechnology." Strategic Management Journal 21.3 (2000): 267-94.

Baysinger, B.D., and A. Zardkoohi. "Technology, Residual Claimants, and Corporate Control." Journal of Law, Economics & Organization 2.2 (1986): 339-50.

"BIO | Biotechnology Industry Facts." BIO | Biotechnology Industry Organization. 2008.

Bosner, Kevin. "Board Composition, Structure, and Financial Performance: An Update." The Journal of Applied Business Research 23.4 (2007): 27-36.

Bratic, V. Walton, Patricia Tilton, and Mira Balkrishnan, 1997. "Navigating through a Biotech Valuation." Journal of Biotechnology in Healthcare Research and Regulation, Vol. 4, 207–216.

Dalton, D., C. Daily, A. Ellstrand, and J. Johnson. "Meta-analytic reviews of board composition, leadership structure, and financial performance." Strategic Management Journal 19.3 (1998): 269-90.

DiMasi, J. A. "Success rates for new drugs entering clinical testing in the United States." Clinical Pharmacology and Therapeutics 58 (1995): 1-14.

DiMasi, J. A., R. W. Hansen, and H. G. Grabowski, 2003. “The price of innovation: new estimates of drug development costsâ€, Journal of Health Economics 22: 151–185.

EuropaBio, 2011. Available online at:

Finkle, Todd A. "The Relationship between Boards of Directors and Initial Public Offerings in the Biotechnology Industry." Entrepreneurship: Theory & Practice 22.3 (1998): 5-29.

Goodstein, J., K. Gautam, and W. Boeker. "The Effects of Board Size and Diversity on Strategic Change." Strategic Management Journal 15.3 (1994): 241-50.

Guo, R., B. Lev, and N. Zhou. "The valuation of biotech IPOs." Journal of Accounting, Auditing, and Finance 20.4 (2005): 423-59.

Jensen, M., and W. Meckling. "Theory of the Firm: Managerial behavior, agency costs, and ownership structure." Journal of Financial Economics 3 (1976): 305-50. Business Source Premier.

Macus, Mark. "Board Capability: An Interactions Perspective on Boards of Directors and Firm Performance." International Studies of Management & Organization 38.3 (2008): 98-116.

Markarian, G. and A. Parbonetti. "Firm Complexity and Board of Director Composition." Corporate Governance: An International Review 15.6 (2007): 1224-243.

McIntyre, M. L., S. A. Murphy, and P. Mitchell. "The top team: examining board composition and firm performance." Corporate Governance: The International Journal of Effective Board Performance 7.5 (2007): 547-61.

Medtrack, 2012,

Morgan, S., P. Grootendors, J. Lexchine, C. Cunningham, and D. Greyson, 2011. “The cost of drug development: A systematic reviewâ€. Health Policy, Forthcoming, 2011.

Pearce, J. A., and S. A. Zahra. "Board composition from a strategic contingency perspective." Journal of Management Studies 29 (1992): 411-38.

Pfeffer, Jeffrey. "Size and Composition of Corporate Boards of Directors: The Organization and its Environment." Administrative Science Quarterly 17.2 (1972): 218-28.

Pisano, G.P., 2006. “Can Science Be a Business? Lessons from Biotechâ€. Harvard Business Review, October, 2006.

Rockoff, J. D. and Pui-Wing Tam. “Biotech Funding Gets Harder to Find.†Wall Street Journal, (3/19/2012): B1.

Schellenger, M. H., D. D. Wood, and A. Tashakori. "Board of Director Composition, Shareholder Wealth, and Dividend Policy." Journal of Management 15.3 (1989): 457-68.

Vance, S. C. "Boards of Directors: Structure and Performance." University of Oregon Press (1964).

Vance, S. C. "Corporate Leadership: Boards, directors, and strategy." (1983).

Villiger, R., and B. Bogdan. "Valuing Pharma R&D: The catch-22 of DCF." Journal of Applied Corporate Finance 17.2 (2005): 113-16.

Villiger, R., and B. Bogdan. "Getting Real About Valuations in Biotech ." Nature Biotechnology, 23 (2006), 423 – 428.

Xu, Bixia. "Investment success and the value of investment opportunities: evidence from the biotech industry." Applied Financial Economics 19.7 (2009): 527-37.

Xu, Bixia, Michel L. Magnan, and Paul E. Andre. "The Stock Market Valuation of R&D Information in Biotech Firms." Contemporary Accounting Research 24.4 (2007): 1291-318.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.